First in Human Study of M1069 in Advanced Solid Tumors

Inclusion Criteria: * Participants who had histologically or cytologically proven locally advanced or metastatic solid malignancies and who are refractory to or have progressed under standard treatment or for whom standard treatment is not expected to deliver clinical benefit * Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 at Screening * Adequate hematological function, hepatic function and renal function * Ability to swallow oral dose forms (for example \[e.g.\] capsules) * Fresh tumor biopsies mandatory for participants at Dose level 2 (DL2) and 6 participants upon potential determination of Recommended Dose for Expansion (RDE). Providing consent to fresh tumor biopsies taken during the Screening period and an on-treatment biopsy is mandatory * Life expectancy of at least 12 weeks according to Investigator judgement * Measurable disease according to The Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 * Other protocol defined inclusion criteria could apply Exclusion Criteria: * Persisting toxicity related to prior therapy Grade greater than (\>) 1 National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0, however, alopecia, sensory neuropathy hypothyroidism and diabetes mellitus Grade less than or equal to (\<=) 2, despite treatment, are allowed * Prior organ transplantation including allogeneic stem cell transplantation * Participants with known brain metastases, except those meeting the following cri…